^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19-7×19 CAR-T

    i
    Other names: CD19-7×19 CAR-T, CD19 CAR-T cells co-expressing IL-7 and CCL19, CD19 CAR-T expressing IL7 and CCL19
    Associations

    News

    Trials
    Company:
    Zhejiang University
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Objective: This study systematically explore the efficacy and safety of fourth-generation chimeric antigen receptor T-cells (CAR-T), which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19, in relapsed or refractory large B-cell lymphoma. Cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome were controllable, and no immune-related adverse reactions occurred. Autologous 7×19 CAR-T combined with tirelizumab for treating relapsed or refractory large B-cell lymphoma achieved good efficacy with controllable adverse reactions.
    Journal
    |
    CD19 (CD19 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • IL7 (Interleukin 7)
    |
    CD19 expression
    |
    Tevimbra (tislelizumab) • CD19-7×19 CAR-T
    over1year
    CICPD: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PD-1 (Programmed cell death 1) • CCL19 (C-C Motif Chemokine Ligand 19) • IL7 (Interleukin 7)
    |
    CD19 expression
    |
    Tevimbra (tislelizumab) • CD19-7×19 CAR-T
    over1year
    CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL (clinicaltrials.gov)
    P1, N=24, Recruiting, Ningbo No. 1 Hospital
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    Tevimbra (tislelizumab) • CD19-7×19 CAR-T
    over2years
    Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741) (ASH 2021)
    CD19- 7×19 CA R-T cells were administrated at dose of 1 to 3 × 10 6 CAR-T cells/kg following lymphodepleting chemotherapies using fludarabine (30 mg/m 2 ) and cyclophosphamide (500 mg/m 2 ). At 30th day after modified T-cells infusion, patients received 6 cycles of anti-PD-1 antibody Tislelizumab (200mg) for every 3 weeks...However, it remains unclear whether long term remission rate can be achieved. Long term follow-up and additionally enrolled patients would be necessary.
    Clinical • Combination therapy • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CCL19 (C-C Motif Chemokine Ligand 19)
    |
    PD-L1 expression • CD19 expression
    |
    Tevimbra (tislelizumab) • cyclophosphamide • fludarabine IV • CD19-7×19 CAR-T